Valneva (NASDAQ:VALN - Get Free Report) had its price objective dropped by equities researchers at HC Wainwright from $19.00 to $18.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm presently has a "buy" rating on the stock. HC Wainwright's price target points to a potential upside of 282.57% from the company's previous close.
Valneva Trading Up 1.6 %
Valneva stock traded up $0.08 during trading on Thursday, reaching $4.71. The company had a trading volume of 58,416 shares, compared to its average volume of 43,782. Valneva has a 12-month low of $3.62 and a 12-month high of $9.50. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.25 and a current ratio of 2.78. The stock's 50 day moving average price is $4.29 and its two-hundred day moving average price is $5.80. The firm has a market capitalization of $382.33 million, a price-to-earnings ratio of -36.15 and a beta of 1.93.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in Valneva stock. AlphaCentric Advisors LLC grew its position in Valneva SE (NASDAQ:VALN - Free Report) by 33.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 118,000 shares of the company's stock after purchasing an additional 29,748 shares during the period. AlphaCentric Advisors LLC owned approximately 0.15% of Valneva worth $717,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 11.39% of the company's stock.
Valneva Company Profile
(
Get Free Report)
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.
Further Reading
Before you consider Valneva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Valneva wasn't on the list.
While Valneva currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
